3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors

Patent metadata

Field	Value
Publication number	US-8969583-B2
Application number	US-201213728502-A
Country	US
Kind code	B2
Filing date	Dec 27, 2012
Priority date	Dec 28, 2011
Publication date	Mar 3, 2015
Grant date	Mar 3, 2015

Abstract

This invention is directed to a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 , R 3 , n, X 1 , X 2 , L 1 , and L 2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

First claim

What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
X 1 is N and X 2 is S;
L 1 is selected from the group consisting of —N(R)—, —N(R)—C(═O)—N(R)—, —O—C(═O)—N(R)—, —N(R)—C(═O)— and —C(═O)—N(R)—;
L 2 is selected from the group consisting of a covalent bond, —N(R)—, —N(R)—C(═O), —C(═O)—N(R)— and —N(R)—C(═O)—N(R)—;…

Assignees

• Allergan Inc

Inventors

• Malone Thomas C
• Hull C Eugene Iii
• Boral Sougato
• Wurster Julie A
• Robinson Michael R
• Edelman Jeffrey L

Classifications

• A61P35/00

  Human Necessities · mapped topic

• C07D417/12 Primary

  Chemistry & Metallurgy · mapped topic

• A61P3/00

  Human Necessities · mapped topic

• C07D295/13

  Chemistry & Metallurgy · mapped topic

• C07D275/03

  Chemistry & Metallurgy · mapped topic